Expanded Access Program (EAP): Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Overview

  • Study IDs

  • Site IRB
    • Scottsdale/Phoenix, Arizona: 14-001144
    • Jacksonville, Florida: 14-001144
    • Rochester, Minnesota: 14-001144
    NCT ID: NCT02141087
    Sponsor Protocol Number: PIPF-031

About this study

This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  1. Clinical and radiographic diagnosis of IPF including the presence of usual interstitial pneumonia (UIP) pattern or possible UIP pattern on historical HRCT (ATS 2011).
  2. %FVC ≥ 50% and %DLCO ≥ 30% based either on historical pulmonary function tests obtained in the 30 days prior to screening or on tests obtained during screening.
  3. Able to understand the importance of adherence to program treatment (pirfenidone) and protocol, and willing to follow all program requirements, including the concomitant medication restrictions, throughout the program.
  4. Able to understand and sign a written informed consent form.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the program:

  1. Is receiving an investigational agent (defined as any drug that has not been approved for marketing for any indication in the US); prior use of pirfenidone is permitted.
  2. Has received fluvoxamine therapy ≤ 28 days prior to the first dose of program treatment (pirfenidone) in PIPF-031, or is unable or unwilling to avoid fluvoxamine for the duration of the program.
  3. Has any known contraindication for the use of pirfenidone, specifically
    • Hypersensitivity to the active substance or to any of the drug product excipients
    • Severe hepatic impairment including end stage liver disease
    • Severe renal impairment (CrCl < 30 mL/min) including end stage renal disease requiring dialysis
  4. History of cigarette smoking within 3 months prior to the completion of screening or is unwilling to avoid tobacco products throughout program.
  5. Known explanation for interstitial lung disease other than IPF, including but not limited to radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV) infection, viral hepatitis, and cancer.
  6. History of clinically significant environmental exposure known to cause pulmonary fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds.
  7. Pregnancy or lactation. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of participation in the program. If abstinence is not practiced, one of the two methods of birth control should be a hormonal contraceptive (e.g., oral contraceptive and a spermicide).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jay Ryu, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

Jay Ryu, M.D.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Jay Ryu, M.D.

Closed for enrollment

.
CLS-20143405

Mayo Clinic Footer